Total Clinical Event Burden With Edoxaban Monotherapy Versus Dual Antithrombotic Therapy in Atrial Fibrillation and Stable Coronary Artery Disease: Insights From the EPIC‐CAD Trial
Journal of the American Heart Association · 07.07.2026 · 15 (13)
DOI: 10.1161/jaha.125.047672 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 07.07.2026. Verfasst von Sung-Hwan Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Asan Medical Center Seoul Republic of Korea. Hauptthemen laut MEDLINE: Atrial Fibrillation, Coronary Artery Disease, Factor Xa Inhibitors, Fibrinolytic Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Oral anticoagulation is essential for stroke prevention in atrial fibrillation, whereas antiplatelet therapy remains standard for coronary artery disease (CAD), raising concerns about bleeding when both are combined. The effect of these regimens on recurrent events, reflecting cumulative disease burden, has not been fully evaluated.
Methods
This post hoc analysis of the EPIC‐CAD (Edoxaban Versus Edoxaban With Antiplatelet Agent in Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease) trial included 1040 patients with atrial fibrillation and stable CAD randomized to edoxaban monotherapy or edoxaban plus a single antiplatelet agent. The primary end point was the total number of net adverse clinical events at 12 months.
Results
Over a median follow‐up of 12.1 months, 155 total events occurred (123 first, 32 subsequent). Event rates were lower with edoxaban monotherapy than with dual therapy (9.4 versus 19.8 per 100 person‐years; incidence rate ratio, 0.47 [95% CI, 0.34–0.67]). Monotherapy reduced first events (incidence rate ratio, 0.46 [95% CI, 0.32–0.68]) and showed a lower cumulative hazard of total events (hazard ratio, 0.48 [95% CI, 0.32–0.71]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology Asan Medical Center Seoul Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine The Catholic University of Korea Seoul Republic of Korea.
- Department of Biostatics Asan Medical Center Seoul Republic of Korea.
ORCID-Profile: Sung-Hwan Kim, Min Soo Cho, Soyoon Park, Young Choi, Jung-Bok Lee, Duk-Woo Park, Gi-Byoung Nam
Zitieren
APA
Kim, S. H., Cho, M. S., Park, S., Choi, Y., Lee, J. B., Park, D. W., Nam, G. B., & Oh, Y. S. (2026). Total Clinical Event Burden With Edoxaban Monotherapy Versus Dual Antithrombotic Therapy in Atrial Fibrillation and Stable Coronary Artery Disease: Insights From the EPIC‐CAD Trial. Journal of the American Heart Association, 15(13). https://doi.org/10.1161/jaha.125.047672
Vancouver
Kim SH, Cho MS, Park S, Choi Y, Lee JB, Park DW, et al. Total Clinical Event Burden With Edoxaban Monotherapy Versus Dual Antithrombotic Therapy in Atrial Fibrillation and Stable Coronary Artery Disease: Insights From the EPIC‐CAD Trial. Journal of the American Heart Association. 2026;15(13). doi:10.1161/jaha.125.047672
BibTeX
@article{Kim2026,
author = {Kim, Sung-Hwan and Cho, Min Soo and Park, Soyoon and Choi, Young and Lee, Jung-Bok and Park, Duk-Woo and Nam, Gi-Byoung and Oh, Yong-Seog},
title = {Total Clinical Event Burden With Edoxaban Monotherapy Versus Dual Antithrombotic Therapy in Atrial Fibrillation and Stable Coronary Artery Disease: Insights From the EPIC‐CAD Trial},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {13},
doi = {10.1161/jaha.125.047672}
}
EUVIMED